Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
FierceBiotech
Biotech's top 10 money raisers of 2020
In 2020, the biotech sector raised just under $20 billion, outstripping 2018 on every measure, except the total number of financing rounds. 2020 saw 448 venture financing…
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
FierceBiotech
Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out
Ipatasertib, originally developed with Assay, had been forecast to top $1.1 billion in worldwide sales in 2026, according to EvaluatePharma’s consensus, with Jefferies…
FierceBiotech
Novartis set to answer inclisiran's FDA rebuff by Q3. But what about an approval timeline?
Novartis has high hopes for this PCSK9 drug, which it essentially paid $9.7 billion for. Analysts at Evaluate Pharma recently pegged its 2026 sales at $2 billion.
Wall Street Journal
Gilead Reaches Deal to Buy Immunomedics for $21 Billion
Breast-cancer treatment is one of the most lucrative segments of the world-wide cancer-drugs market, which EvaluatePharma pegs at $157 billion this year.
Wall Street Journal
Samsung’s Drugmaking Future Includes a $2 Billion ‘Super Plant’ Bigger Than the Louvre
Biotechnology currently makes up 30% of global sales of prescription and over-the-counter medication, and these drugs are expected to expand by another 5 percentage…
Nature Biopharma Dealmakers
Next-generation therapeutics sustain momentum
The next-generation therapeutics space has continued to progress on several fronts in the past 12 months, but this could be set to change as the industry copes with the…
Financial Times
Drug wars: how AstraZeneca overtook GSK in UK pharma
By 2022, AstraZeneca is expected to return to the ranks of the world’s top 10 pharma companies thanks to its new blockbuster drugs, according to data provider…
